• Arrowhead Pharmaceuticals recently presented interim Phase 1/2a data for obesity and MASH candidate ARO-INHBE and new clinical findings for triglyceride-lowering therapy plozasiran, while also outlining upcoming clinical and commercial milestones during its Jefferies Global Healthcare Conference 2026 appearance.
• The emerging profile of ARO-INHBE as a potential infrequently dosed obesity and MASH treatment, together with expanded plozasiran data in patients with renal and hepatic impairment, highlights Arrowhead’s ambition to build a broader cardiometabolic franchise around its RNA-based platform.
• We'll now examine how promising ARO-INHBE obesity and MASH data could reshape Arrowhead's investment narrative around cardiometabolic and RNAi leadership.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead today, you need to believe its RNAi platform can translate into durable cardiometabolic franchises while the company manages heavy R&D and commercial spending before consistent profitability. Near term, the most important catalyst remains pivotal plozasiran readouts in severe hypertriglyceridemia, and this week’s ARO-INHBE data does not change that. The biggest risk is that rising trial and launch costs outpace revenue, potentially increasing the need for fresh capital if milestones or launches underperform.

The ARO-INHBE Phase 1/2a data are especially relevant here because they strengthen Arrowhead’s broader cardiometabolic story around REDEMPLO and the upcoming SHASTA-3 and SHASTA-4 results. Early signs of durable liver fat and visceral adipose reductions, including in combination with tirzepatide, reinforce the idea that Arrowhead is building a multi-asset obesity and MASH franchise on the same RNAi backbone that powers plozasiran. How efficiently the company funds this expanding pipeline without excessive dilution will be critical for shareholders.

Yet while the cardiometabolic story is getting stronger, investors should also be aware that...

Arrowhead Pharmaceuticals' narrative projects $398.8 million revenue and $64.0 million earnings by 2028.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 12% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$1.2 billion by 2029, but with ARO-INHBE and plozasiran both advancing, you should recognize that views differ widely on whether Arrowhead’s high cash burn and potential dilution risks justify those assumptions, and that this new data could shift both bullish and cautious narratives from here.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.